0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Special Feature |  FREE
Arch Pediatr Adolesc Med. 2012;166(4):378-379. doi:10.1001/archpediatrics.2011.875b.

Special Feature |  FREE
Arch Pediatr Adolesc Med. 2008;162(10):990. doi:10.1001/archpedi.162.10.990.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Dermatology
Original Investigation  | 
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis:  Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Robert E. Kalb, MD; David F. Fiorentino, MD, PhD; Mark G. Lebwohl, MD; et al.
JAMA Dermatology
Original Investigation  | 
CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis:  A Randomized Clinical Trial
Ari M. Goldminz, MD; Mayte Suárez-Fariñas, PhD; Andrew C. Wang, MD; et al.
JAMA Dermatology
Research Letter  | 
Open-Label Trial of MABp1, a True Human Monoclonal Antibody Targeting Interleukin 1α, for the Treatment of Psoriasis
Kyle M. Coleman, MD; Johann E. Gudjonsson, MD, PhD; Michael Stecher, MD
JAMA Dermatology
Original Investigation  | 
Systemic Therapy for Psoriasis and the Risk of Herpes Zoster:  A 500 000 Person-year Study
Guy Shalom, MD, MHA; Devy Zisman, MD; Haim Bitterman, MD; et al.